Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Vaccine

• Publication date

  2015-11-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2015.10.115PMID 26541135PMCID PMC4679420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increasing uptake of live attenuated influenza vaccine among children in the United States, 2008-2014.

  2015cited by this paper
• Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.

  2015cited by this paper
• Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

  2014cited by this paper
• Intravascular staining for discrimination of vascular and tissue leukocytes

  2014cited by this paper
• Novel vaccination strategies against tuberculosis.

  2014cited by this paper
• Intranasal formulations: promising strategy to deliver vaccines

  2014cited by this paper
• Cutting Edge: Control of Mycobacterium tuberculosis Infection by a Subset of Lung Parenchyma–Homing CD4 T Cells

  2014cited by this paper
• Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity

  2014cited by this paper
• Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity.

  2014cited by this paper
• Mucosal and Systemic Immune Responses to Mycobacterium tuberculosis Antigen 85A following Its Co-Delivery with CpG, MPLA or LTB to the Lungs in Mice

  2013cited by this paper
• Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

  2013cited by this paper
• Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

  2013cited by this paper
• The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine

  2012cited by this paper
• Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140

  2012cited by this paper
• The mucosal vaccine quandary: Intranasal vs. sublingual immunization against influenza

  2012cited by this paper
• A Gamma Interferon Independent Mechanism of CD4 T Cell Mediated Control of M. tuberculosis Infection in vivo

  2011cited by this paper
• Norovirus vaccine against experimental human Norwalk Virus illness.

  2011cited by this paper
• A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis

  2010cited by this paper
• Cell-mediated immune responses in tuberculosis.

  2009cited by this paper
• Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH-17 cells

  2009cited by this paper
• Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis1

  2008cited by this paper
• Translational Mini‐Review Series on Toll‐like Receptors:
Toll‐like receptor ligands as novel pharmaceuticals for allergic disorders

  2007cited by this paper
• Drying a tuberculosis vaccine without freezing

  2007cited by this paper
• IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge

  2007cited by this paper
• Mucosal Administration of Ag85B-ESAT-6 Protects against Infection with Mycobacterium tuberculosis and Boosts Prior Bacillus Calmette-Guérin Immunity1

  2006cited by this paper
• Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features.

  2006cited by this paper
• Inborn errors of IL-12/23- and IFN-γ-mediated immunity: molecular, cellular, and clinical features

  2006cited by this paper
• Mechanisms of Mucosal and Parenteral Tuberculosis Vaccinations: Adenoviral-Based Mucosal Immunization Preferentially Elicits Sustained Accumulation of Immune Protective CD4 and CD8 T Cells within the Airway Lumen1

  2005cited by this paper
• Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis1

  2004cited by this paper
• Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis.

  2004cited by this paper
• Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis.

  2003cited by this paper
• Requirement of Interleukin 17 Receptor Signaling for Lung Cxc Chemokine and Granulocyte Colony-Stimulating Factor Expression, Neutrophil Recruitment, and Host Defense

  2001cited by this paper
• Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN‐γ in their lungs

  2001cited by this paper
• Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration.

  2000cited by this paper
• A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection

  1999cited by this paper
• Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

  1995cited by this paper
• An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

  1993cited by this paper

• A review of the efficacy of clinical tuberculosis vaccine candidates in mouse models

  2025cites this paper
• Lung IL-17A-Producing CD4+ T Cells Correlate with Protection after Intrapulmonary Vaccination with Differentially Adjuvanted Tuberculosis Vaccines

  2024cites this paper
• Mucosal BCG delivery provides a spectrum of protection from different Mycobacterium tuberculosis strains across susceptible and resistant mouse backgrounds

  2024cites this paper
• Recent Advances in the Development of Mincle-Targeting Vaccine Adjuvants

  2024cites this paper
• MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates

  2024cites this paper
• A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils

  2023cites this paper
• A novel adjuvant formulation induces robust Th1/Th17 memory and mucosal recall responses in Non-Human Primates

  2023cites this paper
• An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis

  2023cites this paper
• Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

  2022cites this paper
• It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity

  2022influential citation
• Development and Testing of a Spray-Dried Tuberculosis Vaccine Candidate in a Mouse Model

  2022cites this paper
• Changes in the Immune Phenotype and Gene Expression Profile Driven by a Novel Tuberculosis Nanovaccine: Short and Long-Term Post-immunization

  2021cites this paper
• Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics

  2021cites this paper
• Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward

  2021cites this paper
• Local Pulmonary Immunological Biomarkers in Tuberculosis

  2021cites this paper
• Synthetic protein conjugate vaccines provide protection against Mycobacterium tuberculosis in mice

  2021influential citation
• Intranasal vaccination with Listeria ivanovii as vector of Mycobacterium tuberculosis antigens promotes specific lung-localized cellular and humoral immune responses

  2020cites this paper
• Intranasal Delivery of Inactivated Influenza Virus and Poly(I:C) Adsorbed Corn-Based Nanoparticle Vaccine Elicited Robust Antigen-Specific Cell-Mediated Immune Responses in Maternal Antibody Positive Nursery Pigs

  2020cites this paper
• Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunity.

  2020cites this paper
• Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants

  2020cites this paper
• Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis

  2020cites this paper
• Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis

  2020cites this paper
• Mucosal vaccination with CysVac2/Advax induces Th17 lung-resident CD4+ T cells and interleukin-17-dependant protection against Mycobacterium tuberculosis infection

  2020cites this paper
• Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model

  2019cites this paper
• Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection

  2019cites this paper
• Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission.

  2019cites this paper
• The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine

  2019cites this paper
• Generation of IL-3–Secreting CD4+ T Cells by Microbial Challenge at Skin and Mucosal Barriers

  2019cites this paper
• Mucosal vaccination with a self-adjuvanted lipopeptide is immunogenic and protective against Mycobacterium tuberculosis.

  2019cites this paper
• Biased Generation and In Situ Activation of Lung Tissue–Resident Memory CD4 T Cells in the Pathogenesis of Allergic Asthma

  2018cites this paper
• SapM mutation to improve the BCG vaccine: genomic, transcriptomic and preclinical safety characterization

  2018cites this paper
• Mesenteric CD103+DCs Initiate Switched Coxsackievirus B3 VP1-Specific IgA Response to Intranasal Chitosan-DNA Vaccine Through Secreting BAFF/IL-6 and Promoting Th17/Tfh Differentiation

  2018cites this paper
• Humoral immune and adjuvant responses of mucosally-administered Tinospora cordifolia immunomodulatory protein in BALB/c mice

  2018cites this paper
• Granzyme B induced by Rv0140 antigen discriminates latently infected from active tuberculosis individuals

  2018cites this paper
• Host resistance to pulmonary Mycobacterium tuberculosis infection requires CD153 expression

  2018cites this paper
• Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells

  2018cites this paper
• Specific T cell induction using iron oxide based nanoparticles as subunit vaccine adjuvant

  2018cites this paper
• Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica

  2018cites this paper
• New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity.

  2018cites this paper
• Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route

  2017cites this paper
• What Have We Learnt about BCG Vaccination in the Last 20 Years?

  2017cites this paper
• Conjugation Reaction with 8-Arm PEG Markedly Improves the Immunogenicity of Mycobacterium tuberculosis CFP10-TB10.4 Fusion Protein.

  2017cites this paper
• Assessment of Antigen-Specific Cellular Immunogenicity Using Intracellular Cytokine Staining, ELISpot, and Culture Supernatants.

  2017cites this paper
• Vaccine Adjuvants

  2017cites this paper
• The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing

  2017influential citation
• Intranasal Vaccination With Salmonella-Derived Serodominant Secreted Effector Protein B Associated With Gas-Filled Microbubbles Partially Protects Against Gut Infection in Mice.

  2016cites this paper
• The Memory Immune Response to Tuberculosis

  2016cites this paper
• Vaccine-induced protective immunity to Bordetella pertussis

  2016cites this paper
• Boosting BCG with inert spores improves immunogenicity and induces specific IL-17 responses in a murine model of bovine tuberculosis.

  2016cites this paper
• Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K.

  2016cites this paper